«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

24卷

期数:

2018年05期

页码:

425-428

栏目:

临床医学

出版日期:

2018-09-20

文章信息/Info

Title:

Prognosis and survival risk factors for 92 advanced hepatocellular carcinoma patients after hepatectomy

作者:

侯振宇; 孔银龙; 孙 林; 宋天强; 张 倜

天津医科大学肿瘤医院肝胆肿瘤科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津300060

Author(s):

HOU Zhen-yu;  KONG Yin-long;  SUN Lin;  SONG Tian-qiang;  ZHANG Ti

1.Department of Hepatobiliary Surgery, Cancer Institute and Hospital ,Tianjin Medical University，National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China

关键词:

肝细胞癌; 晚期肝癌; 肝切除术; 预后; 危险因素

Keywords:

hepatocellular carcinoma;  advanced HCC;  hepatectomy;  prognosis;  risk factors

分类号:

R735.7

DOI:

-

文献标志码:

A

摘要:

目的：探讨行肝切除术的晚期肝细胞癌患者的预后及影响生存的危险因素。方法：回顾性分析 2007年6月-2013年12月在天津医科大学肿瘤医院行肝切除的92例晚期肝癌患者的临床资料，使用K-M法及Log-rank分析筛选可能影响患者预后的相关因素，使用COX回归检验模型明确影响预后的独立危险因素。结果：患者总体的中位生存时间为27.1个月，年龄＜60岁（P =0.001）、AFP≥400 ng/mL（P=0.037）、微血管侵犯（P=0.007）、肝大部切除（P=0.001）为影响患者术后生存的独立危险因素。总体无复发生存时间为13.5个月，AFP≥400 ng/mL（P=0.017）为影响患者术后复发的独立危险因素。结论：部分晚期肝癌患者经肝切除治疗可获得良好的预后。

Abstract:

Objective: To analyze prognosis and survival risk factors for advanced hepatocellular carcinoma (HCC) patients treated by surgery． Methods: Clinical data of 92 patients from Tianjin Medical University Cancer Institute Hospital who underwent surgery from June 2007 to December 2013 were retrospectively studied． Kaplan-Meier method and log-rank test were used to discover potential prognostic factors. The COX proportional hazards models were applied to identify the independent risk factors for survival and disease-free survival. Results: The median overall survival was 27.1 months. Age＜60 year（P=0.001），AFP≥400 ng/mL(P =0.037)，microvessel invasion（P =0.007） and major hepatectomy (P =0.001) were the independent risk factors for overall survival. The median disease-free survival was 13.5 months. AFP≥400 ng/mL(P =0.017) was the independent risk factor for recurrence. Conclusion: Some patients with advanced liver cancer can get a better prognosis after liver resection.

参考文献/References:

[1] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115
[2] Forner A, Llovet J M, Bruix J. Hepatocellular carcinoma[J]. The Lancet, 2012,379(9822):1245
[3] Bruix J, Sherman M, American Association for the Study of Liver Disease. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011,53(3):1020
[4] European Association for the Study of The Liver, European Organisation For Research, Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012,56(4):908
[5] Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J]. Ann Surg, 2014,260(2):329
[6] Sakamoto K, Nagano H. Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus[J]. Hepatol Res,2017,47(10):957
[7] Yang T, Lin C, Zhai J, et al. Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging[J]. J Cancer Res Clin Oncol, 2012,138(7):1121
[8] Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: Is it adherent to the EASL/AASLD recommendations[J]. Ann Surg, 2013,257(5):929
[9] Zhong JH, Rodriguez AC, Ke Y W, et al. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion[J].Medicine (Baltimore), 2015,94(3):e396
[10] Bruix J, Cheng A L, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies[J]. J Hepatol, 2017,67(5): 999
[11] Giannini EG, Bucci L, Garuti F, et al. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice[J]. Hepatology, 2018,67(5):1784
[12] Kokudo T, Hasegawa K, Matsuyama Y, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion[J]. J Hepatol, 2016,65(5):938
[13] Shen J Y, Li C, Wen T F, et al. Alpha fetoprotein changes predict hepatocellular carcinoma survival beyond the Milan criteria after hepatectomy[J]. J Surg Res, 2017,209:102
[14] Silencing alpha-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell[J]. Cancer let，2008， 271(2)：281

相似文献/References:

[1]周冷潇,韩 涛.慢性乙型病毒性肝炎肝硬化发生肝细胞癌的危险因素分析[J].天津医科大学学报,2017,23(03):214.
　ZHOU Leng-xiao,HAN Tao.Risk factors of hepatocellular carcinoma in patients with hepatitis B virus-related liver cirrhosis[J].Journal of Tianjin Medical University,2017,23(05):214.
[2]周冷潇,韩 涛,刘 芳.无创肝纤维化指标结合甲胎蛋白对乙型肝炎相关肝细胞癌的评估[J].天津医科大学学报,2017,23(05):415.
　ZHOU Leng-xiao,HAN Tao,LIU Fang.Assessment of non-invasive fibrosis indexes with alpha-fetoprotein?for? hepatitis B virus-related hepatocellular carcinoma[J].Journal of Tianjin Medical University,2017,23(05):415.
[3]张自立,石文霞,李 霖,等.肝癌血清中miRNA-183的表达及临床意义[J].天津医科大学学报,2017,23(06):519.
　ZHANG Zi-li,?SHI Wen-xia,LI Lin,et al.Expression and significance of serum microRNA-183 in hepatocellular carcinoma[J].Journal of Tianjin Medical University,2017,23(05):519.
[4]胡 源,许戈良,荚卫东,等.C1QL1蛋白在原发性肝细胞癌中的表达及其临床意义[J].天津医科大学学报,2019,25(04):329.
　HU Yuan,XU Ge-liang,JIA Wei-dong,et al.Expressions of C1QL1 protein inprimaryhepatocellular carcinoma and its clinical significance[J].Journal of Tianjin Medical University,2019,25(05):329.
[5]张萃萃,邓为民.基因表达谱分析肝细胞癌的特征基因[J].天津医科大学学报,2020,26(06):514.
　ZHANG Cui-cui,DENG Wei-min.Gene expression profiling reveals important characteristic genes in hepatocellular carcinoma[J].Journal of Tianjin Medical University,2020,26(05):514.
[6]张杨,游阿彬,齐寒,等.负载化疗药物的外泌体对肝癌的靶向治疗研究[J].天津医科大学学报,2021,27(03):229.
　ZHANG Yang,YOU A-bin,QI Han,et al.Tumor-derived exosomes mediate targeted therapy in hepatocellular carcinoma mice[J].Journal of Tianjin Medical University,2021,27(05):229.
[7]王凤松,朱刘洋,白易,等.基于肿瘤突变负荷构建肝细胞癌风险评分预后模型[J].天津医科大学学报,2022,28(01):20.
　WANG Feng-song,ZHU Liu-yang,BAI Yi,et al.Identification of a risk score prognostic model of hepatocellular carcinoma based on tumor mutation burden[J].Journal of Tianjin Medical University,2022,28(05):20.
[8]赵耕,张盈莹,卓永,等.藏区慢性乙型肝炎患者使用PAGE-B模型对肝细胞癌的风险预测研究[J].天津医科大学学报,2022,28(06):654.
　ZHAO Geng,ZHANG Ying-ying,ZHUO Yong,et al.Risk prediction of hepatocellular carcinoma using the PAGE-B model in Tibetan patients with chronic hepatitis B[J].Journal of Tianjin Medical University,2022,28(05):654.
[9]张华,范松,刘冀琴,等.miR-129-5p通过靶向SALL4抑制肝癌细胞增殖、迁移和侵袭的实验研究[J].天津医科大学学报,2024,30(01):11.[doi:10.20135/j.issn.1006-8147.2024.01.0011]
　ZHANG Hua,FAN Song,LIU Jiqin,et al.The experimental study of miR-129-5p inhibiting proliferation， migration， and invasion of hepatocellular carcinoma by targeting to SALL4[J].Journal of Tianjin Medical University,2024,30(05):11.[doi:10.20135/j.issn.1006-8147.2024.01.0011]
[10]元喆悦,白易,童文,等.基于COVID-19相关基因的肝细胞癌分子分型及预后模型构建与验证[J].天津医科大学学报,2024,30(01):15.[doi:10.20135/j.issn.1006-8147.2024.01.0015]
　YUAN Zheyue,BAI Yi,TONG Wen,et al.Molecular typing of hepatocellular carcinoma based on COVID-19 related genes and construction and validation of prognostic model[J].Journal of Tianjin Medical University,2024,30(05):15.[doi:10.20135/j.issn.1006-8147.2024.01.0015]

备注/Memo

备注/Memo:

作者简介 侯振宇（1993-），男，硕士在读，研究方向：肝胆肿瘤；通信作者：张倜，E-mail: zhangti@tjmuch.com；宋天强，E-mail：tjchi@hotmail.com。

常用功能

更新日期/Last Update: 2018-09-30